Structure-based epitope and PEGylation sites mapping of phenylalanine ammonia-lyase for enzyme substitution treatment of phenylketonuria.

[1]  Hong Zhao,et al.  Structure-function engineering of interferon-beta-1b for improving stability, solubility, potency, immunogenicity, and pharmacokinetic properties by site-selective mono-PEGylation. , 2006, Bioconjugate chemistry.

[2]  P. Carter.  Potent antibody therapeutics by design , 2006, Nature Reviews Immunology.

[3]  M. Hershfield,et al.  Control of hyperuricemia in subjects with refractory gout, and induction of antibody against poly(ethylene glycol) (PEG), in a phase I trial of subcutaneous PEGylated urate oxidase , 2005, Arthritis research & therapy.

[4]  R. Stevens,et al.  Structure-based chemical modification strategy for enzyme replacement treatment of phenylketonuria. , 2005, Molecular genetics and metabolism.

[5]  R. Stevens,et al.  Development of pegylated forms of recombinant Rhodosporidium toruloides phenylalanine ammonia-lyase for the treatment of classical phenylketonuria. , 2005, Molecular therapy : the journal of the American Society of Gene Therapy.

[6]  J. Foote,et al.  Immunogenicity of engineered antibodies. , 2005, Methods.

[7]  W. Martin,et al.  De-immunization of therapeutic proteins by T-cell epitope modification. , 2005, Developments in biologicals.

[8]  G. Schulz,et al.  Structural Basis for the Entrance into the Phenylpropanoid Metabolism Catalyzed by Phenylalanine Ammonia-Lyase , 2004, The Plant Cell Online.

[9]  A. Boodhoo,et al.  Crystal structure of phenylalanine ammonia lyase: multiple helix dipoles implicated in catalysis. , 2004, Biochemistry.

[10]  Huub Schellekens,et al.  Structure-Immunogenicity Relationships of Therapeutic Proteins , 2004, Pharmaceutical Research.

[11]  P. Bugelski,et al.  Predictive power of preclinical studies in animals for the immunogenicity of recombinant therapeutic proteins in humans. , 2004, Current opinion in molecular therapeutics.

[12]  S. A. Marshall,et al.  Minimizing the immunogenicity of protein therapeutics. , 2004, Drug discovery today.

[13]  C. Scriver,et al.  The Metabolic and Molecular Bases of Inherited Disease, 8th Edition 2001 , 2001, Journal of Inherited Metabolic Disease.

[14]  O. Giardini,et al.  Neonatal mass screening for metabolic disorders , 1981, European Journal of Pediatrics.

[15]  Anne S De Groot,et al.  Bioinformatics tools for identifying class I-restricted epitopes. , 2003, Methods.

[16]  J. M. Harris,et al.  Effect of pegylation on pharmaceuticals , 2003, Nature Reviews Drug Discovery.

[17]  J. Sidney,et al.  Rationally engineered proteins or antibodies with absent or reduced immunogenicity. , 2002, Current medicinal chemistry.

[18]  D. Wyss,et al.  Structural and biological characterization of pegylated recombinant interferon alpha-2b and its therapeutic implications. , 2002, Advanced drug delivery reviews.

[19]  Jing-zhong Liu,et al.  STUDY ON A NOVEL STRATEGY TO TREATMENT OF PHENYLKETONURIA , 2002, Artificial cells, blood substitutes, and immobilization biotechnology.

[20]  Damon L. Meyer,et al.  Reduced antibody response to streptavidin through site‐directed mutagenesis , 2001, Protein science : a publication of the Protein Society.

[21]  Zhi-xin Xu,et al.  Rational design of a potent, long-lasting form of interferon: a 40 kDa branched polyethylene glycol-conjugated interferon alpha-2a for the treatment of hepatitis C. , 2001, Bioconjugate chemistry.

[22]  D. Collen,et al.  Recombinant staphylokinase variants with reduced antigenicity due to elimination of B-lymphocyte epitopes. , 2000, Blood.

[23]  J. McDonald,et al.  A heteroallelic mutant mouse model: A new orthologue for human hyperphenylalaninemia. , 2000, Molecular genetics and metabolism.

[24]  G. Schulz,et al.  Crystal structure of histidine ammonia-lyase revealing a novel polypeptide modification as the catalytic electrophile. , 1999, Biochemistry.

[25]  T. Chang,et al.  A different approach to treatment of phenylketonuria: phenylalanine degradation with recombinant phenylalanine ammonia lyase. , 1999, Proceedings of the National Academy of Sciences of the United States of America.

[26]  H. Levy.  Phenylketonuria: old disease, new approach to treatment. , 1999, Proceedings of the National Academy of Sciences of the United States of America.

[27]  A. Kramer,et al.  Antigen sequence- and library-based mapping of linear and discontinuous protein-protein-interaction sites by spot synthesis. , 1999, Current topics in microbiology and immunology.

[28]  A. D. De Groot,et al.  Prediction of well-conserved HIV-1 ligands using a matrix-based algorithm, EpiMatrix. , 1998, Vaccine.

[29]  A. Kramer,et al.  Synthesis and screening of peptide libraries on continuous cellulose membrane supports. , 1998, Methods in molecular biology.

[30]  R. Frank,et al.  SPOT synthesis. Epitope analysis with arrays of synthetic peptides prepared on cellulose membranes. , 1996, Methods in molecular biology.

[31]  Ruurd van der Zee,et al.  Prediction of sequential antigenic regions in proteins , 1985, FEBS letters.

[32]  J. Stephenson,et al.  Molecular cloning of the phenylalanine ammonia lyase gene from Rhodosporidium toruloides in Escherichia coli K-12 , 1985, Journal of bacteriology.

[33]  J. Hoskins,et al.  The metabolism of cinnamic acid by healthy and phenylketonuric adults: a kinetic study. , 1984, Biomedical mass spectrometry.

[34]  J. Hoskins,et al.  Phenylalanine ammonia lyase in the management of phenylketonuria: the relationship between ingested cinnamate and urinary hippurate in humans. , 1982, Research communications in chemical pathology and pharmacology.

[35]  K. R. Woods,et al.  Prediction of protein antigenic determinants from amino acid sequences. , 1981, Proceedings of the National Academy of Sciences of the United States of America.

[36]  I. Snapper,et al.  Cinnamic Acid Metabolism in Man , 1940 .